Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19

NCT04486508 is registered in ClinicalTrials.gov with Rajaie Cardiovascular Medical and Research Center as lead sponsor.

NCT NCT04486508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04486508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19
Lead sponsor
Rajaie Cardiovascular Medical and Research Center
Phase
Phase 3
Overall status
Completed
Start date
July 30, 2020
Completion date
July 5, 2021
Enrollment
600 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19